News Page
Published November 21, 2025
DexCom promised a life-saving G7 glucose monitor that was supposed to be the most accurate ever made. Investors believed it. But now, the truth isn’t so sweet.
From mid-2024 through 2025, DexCom told investors the G7 was safe, reliable, and improving every quarter. Behind the scenes, the company secretly changed the G7’s sensor design without FDA approval. This change made readings less accurate, more dangerous, and ultimately deadly.
In March 2025, the FDA warned DexCom that its G6 and G7 devices were “adulterated.” The stock fell about 9%. Later, more documents showed patients were hospitalized and even died after faulty readings. By September, a damning report tied those failures to the unapproved design. DexCom’s stock plunged nearly 12%.
Investors were stunned. Lives were lost. Trust was shattered. Now, more shareholders are joining the lawsuit.